Loxo and Illumina in partnership over diagnostic for cancer drug

April 10 (Reuters) - Loxo Oncology is partnering with genetic testing company Illumina Inc to use Illumina's diagnostic tool alongside larotrectinib, the drug developer's potential blockbuster drug, the companies said on Tuesday.

The partnership will seek approval for a version of the Illumina's test, TruSight Tumor 170, as a companion diagnostic for Loxo's larotrectinib and another one of Loxo's experimental cancer drugs, across tumor types. (Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber)